Tag: non-small cell lung cancer (NSCLC)

1. Atezolizumab significantly increased overall survival compared to platinum-based combination chemotherapy in participants with untreated metastatic non-small-cell lung cancer (NSCLC) and high programmed death 1 ligand (PD-L1) expression. 2. Atezolizumab was associated with longer progression-free survival compared to platinum-based combination chemotherapy. Evidence Rating Level: 1 (Excellent) Study Rundown: The first line-treatment for...
1. Atezolizumab significantly increased overall survival compared to platinum-based combination chemotherapy in participants with untreated metastatic non-small-cell lung cancer (NSCLC) and high programmed death 1 ligand (PD-L1) expression. 2. Atezolizumab was associated with longer progression-free survival compared to platinum-based combination chemotherapy. Evidence Rating Level: 1 (Excellent) Study Rundown: The first line-treatment for...
1. In this retrospective cohort study, there was an observed decrease in mortality in non-small-cell lung cancer patients that corresponded with the approval of targeted therapies 2. The improved mortality of small cell lung cancer was not driven by treatment advancement but rather a decrease in the incidence Evidence Rating Level:...
1. After a 3-year follow-up to a phase 3 trial, the epidermal growth factor receptor-tyrosine kinase inhibitor osimertinib resulted in a longer median overall survival versus comparator EGFR-TKIs with similar safety profiles. 2. Benefits appeared to extend across most predefined subgroups including sex, age, and smoking history, although there was...
1. After a 3-year follow-up to a phase 3 trial, the epidermal growth factor receptor-tyrosine kinase inhibitor osimertinib resulted in a longer median overall survival versus comparator EGFR-TKIs with similar safety profiles. 2. Benefits appeared to extend across most predefined subgroups including sex, age, and smoking history, although there was...
Pembrolizumab is a monoclonal antibody against programmed cell death protein 1 (PD-1). Previous studies have shown that pembrolizumab is effective in prolonging survival in advanced non-small-cell lung cancer (NSCLC) with a PD1-ligand (PD-L1) tumor proportion score (TPS) of 50% or greater. In this randomized, open-label, phase 3 study, pembrolizumab...
1. In patients with non-small cell lung cancer (NSCLC), an analysis of clinical and genomic data from routine care replicated previously established relationships between driver mutations and response to therapy and between tumor mutation burden and response to immunotherapy 2. The study provides confirmation that a multi-institution clinicogenomic database may...
Association of Racial Disparities With Access to Kidney Transplant After the Implementation of the New Kidney Allocation System There are many reasons why a patient may be made inactive on the kidney transplant waiting list, including psychosocial or financial issues or medical comorbidities. This has important implications for a patient’s...